The psoriatic in¯ammatory process is characterized by an overexpression of pro-in¯ammatory cytokines such as tumor necrosis factor-a and interleukin-1b compared with a relative de®ciency of anti-in¯am-matory factors such as interleukin-10 and the interleukin-1 receptor antagonist (interleukin-1Ra). Gene polymorphisms that affect cytokine production may contribute to the disease-associated cytokine imbalance and in¯uence susceptibility to psoriasis. Here, we investigated the relationship between polymorphisms in the genes encoding for tumor necrosis factor-a (G±238A, G±308A), interleukin-1b (C±511T, T+3953C), and interleukin-1Ra (intron 2), and cytokine production in peripheral blood mononuclear cells of healthy donors, and analyzed the distribution of these polymorphisms in patients with psoriasis vulgaris (n = 231) and healthy controls (n = 345). Carriage of tumor necrosis factor A±238 allele 2 (±238*A) was associated with increased production of tumor necrosis factor-a in response to lipopolysaccharide in vitro, and with early onset disease (< 40 y), especially in male patients with psoriasis [32% vs 7% in male controls; odds ratio = 6.78, 95% con®dence interval = (3.18±15.15), p adjusted = 2 Q 10 ±7 ]. Carriage of the interleukin-1B±511*1 (±511*C) homozygous genotype was associated with increased production of interleukin-1Ra in response to lipopolysaccharide and interleukin-10, and with late onset psoriasis [b 40 y; 61% vs 44% in controls; odds ratio = 2.04, 95% con®dence interval = (1.19±3.53), p adjusted = 0.0419]. These ®ndings indicate that gene polymorphisms associated with altered cytokine responses in vitro may modify age of onset of psoriasis. They also provide further evidence that patients with early and late onset psoriasis differ in their genetic background. The mechanisms underlying aberrant cytokine expression in psoriasis remain to be de®ned. Notably, abnormal cytokine levels are detectable not only in cutaneous lesions, but also in nonlesional skin, sera, isolated peripheral blood mononuclear cells, and the synovia of affected joints (Uyemura et al, 1993; Bonifati et al, 1994; Asadullah et al, 1998; Austin et al, 1999) . Hence, discordant cytokine production appears to be a general phenomenon in psoriatic patients, suggesting a genetic predisposition to overproduction of pro-in¯ammatory and/or impaired responsiveness to anti-in¯ammatory signals.
The psoriatic in¯ammatory process is characterized by an overexpression of pro-in¯ammatory cytokines such as tumor necrosis factor-a and interleukin-1b compared with a relative de®ciency of anti-in¯am-matory factors such as interleukin-10 and the interleukin-1 receptor antagonist (interleukin-1Ra). Gene polymorphisms that affect cytokine production may contribute to the disease-associated cytokine imbalance and in¯uence susceptibility to psoriasis. Here, we investigated the relationship between polymorphisms in the genes encoding for tumor necrosis factor-a (G±238A, G±308A), interleukin-1b (C±511T, T+3953C), and interleukin-1Ra (intron 2), and cytokine production in peripheral blood mononuclear cells of healthy donors, and analyzed the distribution of these polymorphisms in patients with psoriasis vulgaris (n = 231) and healthy controls (n = 345). Carriage of tumor necrosis factor A±238 allele 2 (±238*A) was associated with increased production of tumor necrosis factor-a in response to lipopolysaccharide in vitro, and with early onset disease (< 40 y), especially in male patients with psoriasis [32% vs 7% in male controls; odds ratio = 6.78, 95% con®dence interval = (3.18±15.15), p adjusted = 2 Q 10 ±7 ]. Carriage of the interleukin-1B±511*1 (±511*C) homozygous genotype was associated with increased production of interleukin-1Ra in response to lipopolysaccharide and interleukin-10, and with late onset psoriasis [b 40 y; 61% vs 44% in controls; odds ratio = 2.04, 95% con®dence interval = (1.19±3.53), p adjusted = 0.0419]. These ®ndings indicate that gene polymorphisms associated with altered cytokine responses in vitro may modify age of onset of psoriasis. They also provide further evidence that patients with early and late onset psoriasis differ in their genetic background. Key words: cytokine polymorphism/ in¯ammation/skin. J Invest Dermatol 118: 155±163, 2002 P soriasis is a complex in¯ammatory skin disease that involves keratinocyte hyperproliferation and aberrant differentiation, dermal angiogenesis, and a mixed leukocytic in®ltrate composed of activated T cells, neutrophils, and mast cells. The tissue alterations seen in psoriasis are thought to be driven by an exaggerated production of pro-in¯ammatory cytokines, such as tumor necrosis factor (TNF)-a, interferon-g, interleukin (IL)-1b, IL-8, and IL-12 (reviewed in Bos and De Rie, 1999) . On the other hand, there is evidence that anti-in¯ammatory factors, such as IL-10 and the IL-1 receptor antagonist (IL-1Ra), are relatively decreased and their levels insuf®cient to compensate for the increased formation of proin¯ammatory mediators (Gruaz-Chatellard et al, 1991; Bigler et al, 1992; Nickoloff et al, 1994; Asadullah et al, 1998) . The key role of a disturbed cytokine balance in psoriasis is supported by the clinical response to exogenous administration of IL-10 (Reich et al, 2001; Asadullah et al, 2001 ) and anti-TNF-a therapy (Mease et al, 2000; Ogilvie et al, 2001) .
The mechanisms underlying aberrant cytokine expression in psoriasis remain to be de®ned. Notably, abnormal cytokine levels are detectable not only in cutaneous lesions, but also in nonlesional skin, sera, isolated peripheral blood mononuclear cells, and the synovia of affected joints (Uyemura et al, 1993; Bonifati et al, 1994; Asadullah et al, 1998; Austin et al, 1999) . Hence, discordant cytokine production appears to be a general phenomenon in psoriatic patients, suggesting a genetic predisposition to overproduction of pro-in¯ammatory and/or impaired responsiveness to anti-in¯ammatory signals.
Genetic factors are likely to play a fundamental part in the manifestation of psoriasis. The results of family, twin, and human leukocyte antigen (HLA) allotype studies as well as genome-wide scans in affected families all point to a genetic basis for psoriasis susceptibility, which is complex and likely to re¯ect the action of a number of genes (reviewed in Capon et al, 2000) . One of the most consistent observations is the association with genes encoded on the short arm of chromosome 6 within the major histocompatibility complex region. There is also evidence that disease subtypes within psoriasis may differ in their genetic background. Patients with early onset disease (before the age of 40 y) are predominantly carriers of HLA-Cw6, -B57, and -DR7, and often have a positive family history, whereas patients with late onset disease (age at onset b 40 y) often have sporadic disease, and the association with HLA alleles is weaker (reviewed in Henseler, 1998) .
During recent years it has become apparent that many genes encoding important regulatory cytokines are subject to genetic polymorphism in humans, and that variant cytokine alleles can be markers of enhanced susceptibility to immune-mediated diseases (Bidwell et al, 1999) . The gene encoding TNF-a (TNFA; OMIM: *191160) is located centromerically to HLA-B within the major histocompatibility complex class III region (further information on OMIM *191160 is available under http://www.3.ncbi.nlm.nih.-gov/Omim/searchomim.html). It contains a number of polymorphisms, including ®ve microsatellites and several single nucleotide polymorphisms particularly in the promoter region. In Caucasian populations, the most common polymorphisms are two G to A transitions in the promoter at positions ±238 (D'Alfonso and Richiardi, 1994) and ±308 (Wilson et al, 1992) . Current data obtained from reporter gene assays and cell culture experiments suggest that these polymorphisms affect cytokine production; however, their exact functional consequence is still controversial (Pociot et al, 1995; Kroeger et al, 1997 Kroeger et al, , 2000 Wilson et al, 1997; Kaluza et al, 2000) .
Because of its location within the major histocompatibility complex region, the presence of polymorphisms that are likely to in¯uence gene expression, and the key role of aberrant TNF-a expression in psoriasis, TNFA has been considered a candidate gene in psoriasis. We and colleagues have observed an association of allele 2 of the TNFA±238 polymorphism (A at ±238) with the disease in European patients (Arias et al, 1997; Hohler et al, 1997; Reich et al, 1999) , although this was not con®rmed in another report (Jacob et al, 1999) . In concert, the reported ®ndings suggest a considerable variation in the distribution of TNFA polymorphisms among psoriasis subgroups that might be de®ned by gender, age at onset, and a positive or negative family history. Until now, however, this has not been systematically investigated.
Consequently, this study addressed the role of TNFA promoter polymorphisms in psoriasis subgroups. In addition, we re-investigated the functional impact of these polymorphisms on the production of TNF-a in response to pro-in¯ammatory and antiin¯ammatory stimuli in vitro. In light of the important contribution of the IL-1 system to the psoriatic in¯ammatory process (Prens et al, 1996; Wei et al, 1999; Schon et al, 2001) , we extended our investigation to polymorphisms in the genes encoding IL-1b (IL1B; OMIM: *147720) and its natural antagonist, IL-1Ra (IL1RN; OMIM: *147679).
MATERIALS AND METHODS
Patients Unrelated German Caucasian patients with psoriasis (n = 231 cases) were consecutively enrolled from the psoriasis clinic at the Department of Dermatology, University Hospital Go Èttingen (Germany), which longitudinally follows such patients in Southern Lower Saxony. All patients were seen by an experienced dermatologist (K.R.) and recruited if they had an unequivocal clinical diagnosis of psoriasis vulgaris. Patients with psoriasis were considered to have``early onset disease'' if disease onset was before 40 y of age and``late onset disease'' if age at onset was b 40 y according to the classi®cation of Henseler and Christophers (1985) . Healthy unrelated German Caucasians (n = 345) recruited from the blood donor registry of the Department of Transfusion Medicine, University Hospital Go Èttingen, and from among local health care personnel served as controls. Health status was determined by skin examination and a record of the personal and familial medical history. Characteristics of the study participants are shown in Table I . None of the control subjects had a positive family history for psoriasis. The study was approved by the Institutional Review Board of the Medical Faculty of the University of Go Èttingen, and informed consent was obtained from all participants.
Preparation of genomic DNA Peripheral blood (10 ml) was collected in sterile tubes containing ethylenediamine tetraacetic acid as an anticoagulant. Extraction of DNA from buffy coats was performed by a salting out procedure. Brie¯y, lymphocytes were collected at 400 Q g and 4°C, and lyzed in 50 mM Tris±HCl (pH 8.0), 20 mM ethylenediamine tetraacetic acid (pH 8.0), and 2% sodium dodecyl sulfate. Protein was digested with Proteinase K (6 h at 56°C) and pelleted with 6 M NaCl following centrifugation at 5000 Q g for 20 min. DNA was precipitated with 1.5 Q vol. 100% ethanol. DNA yields were between 0.1 and 1 mg per ml.
IL1RN VNTR polymorphism
The fragment of the IL1RN gene containing variable numbers of an identical tandem repeat of 86 bp was ampli®ed by polymerase chain reaction (PCR) with the primers 5¢-CTCAGCAACACTCCTAT-3¢ (sense) and 5¢-TCCTGGTCTGCAGG-TAA-3¢ (anti-sense) as previously described (Tarlow et al, 1993) . Ampli®cation was performed with 2 ml primers (10 pmol per ml; Eurogentec, Seraing, Belgium), 0.9 ml MgCl 2 (50 mM), 3 ml deoxyribonucleoside triphosphates (3.75 mM; Amresco, Solon, Ohio, USA), 0.2 mL TaqPol (5 U per ml; Eurogentec), 3 ml 10 Q Taq buffer (Eurogentec), and 200±600 ng genomic DNA in a ®nal volume of 30 ml. PCR conditions were as follows: initial denaturation at 94°C for 4 min, followed by 32 cycles of denaturation at 94°C for 1 min, annealing at 50°C for 1 min and elongation at 72°C for 1 min with a ®nal elongation at 72°C for 10 min and cooling down to 4°C. PCR products were analyzed by electrophoresis on a 2% agarose gel stained with ethidium bromide. Alleles 1±5 (IL1RN*1±IL1RN*5) were detected according to their size relative to a 100 bp DNA ladder (Gibco BLR, Eggenstein, Germany) as published (Mans®eld et al, 1994) : allele 1 (four repeats) 410 bp; allele 2 (two repeats) 240 bp; allele 3 (®ve repeats) Early onset = age at onset < 40 y; late onset = age at onset b40 y.
b
One or more ®rst-or second-degree relative with psoriasis. 500 bp; allele 4 (three repeats) 325 bp. Allele 5 (six repeats; 595 bp) was not observed in the study population.
IL1B±511 and +3953 polymorphisms The region containing the biallelic polymorphism de®ned by a C to T transition at position ±511 of the IL1B promoter was ampli®ed by PCR using the primers 5¢-TGG-CATTGATCTGGTTCATC-3¢ (sense) and 5¢-GTTTAGGAATCTTC-CCACTT-3¢ (anti-sense) as described (Mans®eld et al, 1994) . The PCR product was digested overnight at 37°C in a total volume of 20 ml containing 0.5 ml AvaI (10 U per ml) and 2 mL AvaI buffer (both from New England Biolab, Schwalbach/Taunus, Germany) and visualized by electrophoresis on a 2.5% agarose gel stained with 0.1% ethidium bromide. As described , digestion of IL1B±511 allele 1 (IL1B±511*1; C at ±511) results in two fragments of 190 and 114 bp, respectively, whereas IL1B±511*2 (IL1B±511*2; T at ±511) is not digested (304 bp). The primers 5¢-GTTGTCATCAGACTTT-GACC-3¢ (sense) and 5¢-TTCAGTTCATATGGACCA-GA-3¢ (antisense) were used to amplify the polymorphic region at position +3953 in exon 5 of the IL1B gene (Bioque et al, 1995) de®ned by a silent T to C transition (Pociot et al, 1994) . The PCR product was subjected to digestion by TaqI (New England Biolab) at 65°C overnight in a reaction volume of 20 ml containing 0.5 ml TaqI (20 U per ml) and 2 ml TaqI buffer (New England Biolab). The 249 bp PCR product either remains intact (C at +3953; allele 2) or is cut in two smaller fragments of 135 bp and 114 bp, respectively (T at +3953; allele 1) (Bioque et al, 1995) . Fragments were visualized as above. PCR conditions for ampli®cation of the IL1B polymorphic regions were as described for IL1RN with the exception that an annealing temperature of 57°C was used.
TNFA promoter polymorphisms The single nucleotide polymorphisms at positions ±238 and ±308 of the TNFA promoter were analyzed by PCR±restriction fragment length polymorphism and allelespeci®c PCR, respectively, as previously described (Couchane et al, 1997; Day et al, 1998) . Variant alleles carrying an A are denoted as allele 2 (TNFA±238*2 and TNFA±308*2, respectively).
Cell culture For functional studies, peripheral blood mononuclear cells (PBMC) were isolated by density gradient centrifugation of heparinized whole blood with Ficoll-Paque (Pharmacia, Freiburg, Germany). All donors were free from clinical disease and did not use medication that might have affected cytokine production. Plasma levels of cortisol and estradiol were determined at the time of blood sampling. PBMC were cultured for 48 h in Iscove's medium supplemented with 10% fetal bovine serum (lot no. 371S), 100 U penicillin G per ml, and 100 mg streptomycin per ml (all purchased from Biochrom KG, Berlin, Germany) at 1 Q 10 6 cells per ml in 24-well¯at bottom culture plates (Greiner, Solingen, Germany) in a 37°C humidi®ed 5% CO 2 atmosphere. Cells were stimulated with either 1 mg lipopolysaccharide (LPS) per ml (Sigma, Deisenhofen, Germany), LPS together with 5 U recombinant human IL-10 per ml (Peprotech, London, U.K.), or left untreated (medium control). Optimal concentrations of stimuli were determined in preliminary experiments. Supernatants were harvested at 2, 4, 8, 24, and 48 h to investigate the kinetics of cytokine release (n = 5 healthy donors). In subsequent experiments, PBMC were isolated from 36 individuals (27 females, nine males; 25±55 y) selected from the healthy control group by quota sampling according to their TNFA and IL1 genotype, and supernatants were harvested at 8 h and 24 h. Protein levels of TNF-a, IL-1b, and IL-1RA were determined by enzymelinked immunosorbent assay according to the manufacturer's instructions (Coulter Immunotech, Marseille, France) (sensitivity TNF-a, 1 pg per ml; IL-1b, 15 pg per ml; IL-1Ra, 30 pg per ml).
Statistical analysis Results of cytokine measurements are given as mean T SEM. Mean values obtained in different groups de®ned by carriage or noncarriage of cytokine gene polymorphisms were compared exploratorily by the asymptotic two-sided unpaired t test with homogeneous variances (prism 2.01; GraphPad, San Diego, CA). IL-1Ra to IL-1b ratios were likewise compared between these groups exploratorily by the asymptotic two-sided Mann±Whitney U test (prism 2.01). In the case of kinetic experiments with different stimuli, IL-1Ra/ IL-1b ratios were evaluated globally by Kruskal±Wallis ANOVA (prism 2.01). Notable differences between the stimuli were then compared exploratorily by the Mann±Whitney U test. Association between in vitro production of IL-1b and IL-1Ra and plasma levels of estradiol or cortisol was estimated by Spearman's correlation coef®cient (prism 2.01).
The frequency of genotypes, including at least one allele 2 at TNFA± 238 and of the *1/1 genotype at IL1B±511 were compared between subgroups by Fisher's two-sided exact test. Odds ratios (OR) and exact 95% con®dence intervals (CI) were computed using StatXact (Version 3.1, Cytel Software Corporation, Cambridge, MA). To correct for multiple testing, the following hierarchical test strategy was adhered to:
1 The genotype frequencies of cases and controls were compared at TNFA±238 and IL1B±511 at a global signi®cance level of 5%. The respective nominal p-values were adjusted according to Bonferroni for conducting two tests.
2 If signi®cant at any of the two loci, genotype frequencies in the groups of cases with early onset of disease, late onset of disease, and controls were compared pairwise. At TNFA±238, a signi®cantly higher frequency of allele 2 in early onset patients over controls has been reported previously (Arias et al, 1997; Hohler et al, 1997; Reich et al, 1999) . Hence, only the comparison of this pair was tested for signi®-cance, the other pairs (late onset cases vs controls and early onset vs late onset cases) were tested merely exploratory. At IL1B±511, however, all three pairs were tested for signi®cance, and the nominal p-values were adjusted for performing three tests according to Shaffer (1986) .
3 If signi®cantly different frequencies were detected between any of these pairs, the same groups were tested separately within each gender and within patients with a positive and a negative family history. To correct for the testing of these two factors, nominal p-values were again adjusted according to Bonferroni. As two subgroups were tested for each factor, nominal p-values were further adjusted for the performance of two tests according to Bonferroni±Holm (Holm, 1979) . Adjusted pvalues < 0.05 were considered signi®cant evidence of association.
To evaluate deviation from the Hardy±Weinberg equilibrium, we exploratorily compared observed and expected frequencies by an exact c 2 -test for goodness of ®t in cases and controls.
RESULTS
TNFA and IL1B promoter polymorphisms affect cytokine production in vitro The effects of IL-10 on the LPS-induced production of TNF-a, IL-1b, and IL-1Ra were studied during 48 h culture of PBMC obtained from ®ve healthy donors (Fig 1) .
As expected, LPS upregulated the release of TNF-a and IL-1b protein, with peak concentrations detectable at 8 h, and IL-10 strongly decreased TNF-a and IL-1b secretion at all time-points (Fig 1a, b) . Induction of IL-1Ra in response to LPS reached a maximum at 24 h. In accordance with earlier results (Jenkins et al, 1994) , addition of IL-10 slightly enhanced IL-1Ra at 4 h, and tended to decrease IL-1Ra levels at 24 h and 48 h (Fig 1c) . A likely explanation is that IL-10 directly enhances IL-1Ra, but inhibits LPS-induced TNF-a, which acts as a strong inducer of IL-1Ra (Danis et al, 1995) . The differential effects of IL-10 on the secretion of IL-1Ra and IL-1b in response to LPS resulted in a notable change of the balance between these two cytokines. At 24 h the molar ratio of secreted IL-1Ra to IL-1b was approximately 2 in response to LPS alone, compared with approximately 25 in response to LPS and IL-10 (exploratory p = 0.0079; Fig 1d) . There were considerable interindividual variations in the cytokine response to LPS and IL-10. In order to investigate whether TNFA and IL1 gene polymorphisms in¯uence cytokine production in our system, 36 individuals from the control group were selected for functional studies by quota sampling according to their IL1 and TNFA genotypes. PBMC derived from carriers of at least one TNFA±238 allele 2 were found to produce more TNF-a in response to LPS than PBMC of carriers of two wild-type alleles [3613 T 590 vs 2095 T 274 pg per 10 6 cells per 8 h (all values mean T SEM); exploratory p = 0.0129]. Furthermore, when cells were additionally treated with IL-10, secreted levels of TNF-a in cultures derived from carriers of promoter polymorphisms remained above those detectable in cultures derived from homozygous wild-type individuals (Fig 2a) ; however, when the inhibitory effect of IL-10 was calculated as percent inhibition of LPS-induced TNF-a secretion on an individual basis, similar values were found in the three genotypic groups (wild-type: 85 T 2%, TNFA±308*2 carriers: 81 T 4%, TNFA±238*2 carriers: 86 T 3%), suggesting that the difference in LPS/IL-10-treated cultures was mainly due to a differential response towards LPS.
PBMC obtained from homozygous carriers of IL1B±511 allele 1 produced more IL-1Ra than PBMC obtained from individuals carrying at least one IL1B±511 allele 2. This effect was observed in cultures stimulated with LPS alone, and was more pronounced in cultures additionally treated with IL-10 (Fig 2b) . In response to LPS/IL-10, the mean production of IL-1Ra was 9618 T 1493 pg per 10 6 cells per 24 h in cultures of IL1B±511*1/1 homozygous donors compared with 4070 T 704 pg per 10 6 cells per 24 h in cultures of carriers of IL1B±511*2 (exploratory p = 0.0072). The amounts of IL-1b (Fig 2b) and TNF-a (not shown) secreted in response to LPS and LPS/IL-10 were similar in these two groups. Calculation of the ratio of IL-1Ra/IL-1b detectable in supernatants of these cultures further underlined the difference in the biologic response. The mean ratio in LPS/IL-10-treated cultures derived from carriers of IL1B±511*2 at 24 h was 16 T 5 compared with 29 T 5 in cultures derived from homozygous carriers of IL1B± 511*1 (exploratory p = 0.0439; Fig 2c) , indicating that the latter were more sensitive to the anti-in¯ammatory effects of IL-10. The effect of the IL1B±511 polymorphism on the IL-Ra to IL-1b ratio was independent of the presence of IL1B + 3953 or IL1RN polymorphisms, and no other associations between carriage of IL1B or IL1RN polymorphisms and secretion levels of IL-1b or IL-1Ra were observed. In addition, there was no difference between male and female donors (exploratory p > 0.05), and no correlation between ex vivo cytokine production and plasma levels of estradiol or cortisol determined at the time of blood sampling.
Association between TNFA±238 promoter polymorphism and early onset psoriasis; effect of gender and family history The absolute and relative frequencies of TNFA promoter genotypes are shown in Table II . No signi®cant deviation from Hardy±Weinberg equilibrium was detected at the TNFA±238 locus in either cases or controls (nominal p > 0.05). In accordance with earlier studies (Hohler et al, 1997) , genotype frequencies at the TNFA±308 locus deviated from Hardy± Weinberg equilibrium in controls (nominal p = 0.0480) but not in cases (nominal p > 0.05).
As expected from previous results, carriers of the TNFA±238*2 allele were signi®cantly more common among patients with psoriasis than among healthy controls [23% vs 8%; OR = 3.24, 95% CI (1.94±5.49); p adjusted = 3 Q 10 ±6 ]. Analyzing subgroups of psoriasis patients separately (Table III) , a signi®cantly higher frequency of TNFA±238*2 allele carriers was detected in patients with early onset of disease (27%) as compared with healthy controls [8%, OR = 4.02 (2.31±7.00); p adjusted = 3 Q 10 ±7 ]. Additionally, when testing this effect within the gender groups, there was evidence for gender-speci®c differences in the role of TNFA± 238*2 as a risk factor for psoriasis. Among male patients with early onset of disease, TNFA±238*2 was signi®cantly over-represented as compared with male controls [32% vs 7%; OR = 6.78 (3.18± 15.15); p adjusted = 2 Q 10 ±7 ], but was similarly distributed among female patients with early disease onset and female controls [16% vs 10%; OR = 1.60 (0.56±4.23); p adjusted = 0.7888]. In contrast, exploratory analysis revealed no enhancement of TNFA±238*2 in patients with late onset psoriasis [17% vs 8% in controls, OR = 1.87 (0.80±4.10); exploratory p = 0.1255] ( Table III) .
As patients with early onset of psoriasis often have a positive family history (Henseler and Christophers, 1985) , we also investigated whether the higher frequency of TNFA±238*2 in early onset patients might be found in patients with either sporadic or familial disease. Carriage of TNFA±238*2 was signi®cantly more common among early onset patients with a positive family history (33%) than among controls [8%, OR = 5.35 (2.90±10.12), p adjusted = 7´10 ±7 ]. Notably, however, TNFA±238*2 was still over-represented in early onset patients with sporadic psoriasis (20%) as compared with healthy controls [8%, OR = 2.77 (1.29± 5.71), p adjusted = 0.0218].
Association between IL1B±511 promoter polymorphism and late onset psoriasis Absolute and relative frequencies of genotypes at the investigated IL1 loci are given in Table II . Genotype frequencies of IL1B and IL1RN polymorphisms in the healthy control group were similar to those reported for healthy European Caucasians in other studies (Bioque et al, 1995; Hacker et al, 1998; Schrijver et al, 1999; El-Omar et al, 2000) , and no signi®cant deviation from Hardy±Weinberg equilibrium was detected at any of the IL1 loci within either cases or controls (all nominal p > 0.05). As can be seen, homozygous carriers of allele 1 of the IL1B±511 promoter polymorphism (IL1B±511*1/1) were signi®cantly more common among patients with psoriasis than among healthy controls [55% vs 44%; OR 1.54 (1.09±2.19); p adjusted = 0.0268]. When patients with early and late disease onset were analyzed separately (Table IV) In the present study, we con®rm and extend previous observations that aberrant cytokine production in psoriasis may at least partly be determined by genetic factors, and provide a new concept for the possible role of cytokine gene polymorphisms in modifying disease onset.
First, our current data support earlier ®ndings that carriage of allele 2 of the TNFA±238 promoter polymorphism (A at ± 238) is associated with psoriasis (Arias et al, 1997; Hohler et al, 1997; Reich et al, 1999) . As TNFA±238*2 was found to correlate with enhanced production of TNF-a in LPS-stimulated PBMC, carriage of this allele may contribute to the increased formation of TNF-a observed in psoriasis.
Overproduction of pro-in¯ammatory mediators may also result from an impaired responsiveness to anti-in¯ammatory signals. In an earlier investigation we obtained evidence that the capacity of exogenous IL-10 to reduce cutaneous TNF-a expression in psoriatic patients is decreased in carriers of variant TNFA alleles as compared with carriers of two wild-type alleles (Reich et al, 2001) . Here, we found that levels of TNF-a in LPS-stimulated PBMC additionally treated with IL-10 were higher in cultures derived from carriers than in those derived from noncarriers of promoter variants, suggesting that these polymorphisms may, in fact, interfere with the control of TNF-a by IL-10. The molecular mechanisms by which TNFA promoter polymorphisms may in¯uence the regulation of TNF-a production remain to be determined. Notably, TNF-a secretion in response to LPS is predominantly regulated at the transcriptional level (Raabe et al, 1998) . The TNFA±238 polymorphism lies in a putative regulatory box of the TNFA gene (D'Alfonso and Richiardi, 1994) , and a repressor site has been localized to a 25 bp interval between positions ± 254 and ± 230 in the promoter (Fong et al, 1995) .
Second, analyzing further the distribution of TNFA polymorphisms in psoriasis subgroups, we con®rmed our earlier ®nding that TNFA±238*2 is a risk factor for psoriasis in males (Reich et al, 1999) . Within males, carriage of TNFA±238*2 was associated with early onset disease; the chance of carrying this allele was approximately 6-fold higher in male patients developing psoriasis before the age of 40 y than in healthy male controls. It has previously been reported that the distribution of age at onset of Protein levels of IL-1Ra (left y-axis) and IL-1b (right y-axis) in culture supernatants at 24 h. Carriers of two copies of IL1B±511*1 (± 511*1/1 homozygous genotype) produced more IL-1Ra than carriers of at least one IL1B±511*2 allele (± 511*2 + ). The difference between these groups was present in cultures treated with LPS alone and in cultures treated with LPS and IL-10. **Exploratory p < 0.01 (t test). (c) The ratio of secreted IL-1Ra to IL-1b at 24 h was higher in ± 511*1/1 homozygous individuals than in carriers of ± 511*2 (*exploratory p < 0.05, Mann±Whitney U test). Bars and error bars represent mean T SEM. n, number of individuals investigated in each group. , adjusted p-value = 3 Q 10 ±6 TNF±238*1/2 and *2/2 psoriasis vs control.
b
Odds ratio = 1.54, 95% con®dence interval = 1.09±2.19, nominal p-value = 0.0135, adjusted p-value = 0.0268 IL1B±511 *1/1 psoriasis vs control. VOL. 118, NO. 1 JANUARY 2002 psoriasis can be explained by two underlying distributions, thus rendering two subtypes of the disease (Henseler and Christophers, 1985) . Within males, the early type shows a peak at about 20 y, the late type at about 60 y; however, there is considerable overlap of the graphs for ages between 25 y and 50 y (Henseler and Christophers, 1985) . Hence, it might be interesting to single out male patients with an unambiguous early disease onset (before age of 25 y) and those with a clear late onset (after age of 50 y). Figure 3 shows an exploratory comparison of the frequencies of TNFA±238*2 carriers in each of these groups. It can be seen that the overrepresentation of TNFA±238*2 carriers in male psoriasis patients is mainly due to the high frequency in the group of patients with an onset earlier than 25 y. Speci®cally, almost half of the male psoriasis patients with this early onset carry the respective allele (47%). In contrast, male patients with a medium age at onset (between 25 y and 49 y) do not differ notably from those with a late onset (19% and 16%, respectively), indicating that TNFA± 238*2 is a marker of very early onset psoriasis in males.
Carriage of TNFA±238*2 was more common among early onset patients with familial as well as sporadic disease compared with healthy controls. Therefore, the effect of TNFA±238*2 seems to be partially independent of the family history. It remains to be further investigated why TNFA±238*2 seems to play a decisive part in psoriasis susceptibility only in males. Interestingly, gender-speci®c differences in the role of variant TNFA alleles as a risk factor for mucocutaneous leishmaniasis and extensive forms of ulcerative colitis have also been reported (Cabrera et al, 1995; Koss et al, 2000) . In concert with the results described here, these ®ndings may indicate a gender-speci®c modulation of the contribution of TNFA polymorphisms to the development of infectious and chronic in¯ammatory diseases. Third, we present ®rst evidence that polymorphisms of the IL1 gene, already implicated in a variety of chronic in¯ammatory and autoimmune conditions, including in¯ammatory bowel disease (Mans®eld et al, 1994; Bioque et al, 1995) , are also part of the genetic components involved in psoriasis. The genes encoding IL-1 and IL-1Ra are clustered together on chromosome 2q14. In the IL1B gene there are two base-exchange polymorphisms at positions ± 511 in the promoter region (di and at position + 3953 in the ®fth exon (Pociot et al, 1994) , and the IL1RN gene has a penta-allelic polymorphic site in intron 2 containing variable numbers of an 86 bp tandem repeat sequence (Tarlow et al, 1993) . Whereas data on the functional consequences of these polymorphisms are partly contradictory (Pociot et al, 1992; Santilla et al, 1998) , recent in vitro and in vivo studies suggest that the production of IL-1b and IL-1Ra is co-ordinately regulated by IL1B and IL1RN alleles (Hurme and Santtila, 1998; Santilla et al, 1998) , possibly through the existence of ®xed haplotypes at these loci and the presence of shared regulatory elements. This interaction may re¯ect the biologic role of the IL-1 system, which is determined by the balance between IL-1 agonists and antagonists (reviewed in Dinarello, 2000) .
We found in our study groups that carriage of the IL1B±511*1/1 genotype is signi®cantly more common in patients with late onset, but not in those with early onset psoriasis as compared with healthy controls. Tarlow et al (1997) reported a decreased frequency of IL1RN allele 2 in patients with late onset psoriasis (age of onset > 40 y), but the ®nding was only of borderline signi®cance, and polymorphisms of the IL1B gene were not investigated. In light of our new ®nding of a signi®cant overrepresentation of the IL1B± 511*1/1 genotype among patients with late onset psoriasis, and given the strong association between IL1B±511 allele 1 and IL1RN allele 1 (Hurme and Santtila, 1998; El-Omar et al, 2000) , the observation by Tarlow et al (1997) may re¯ect linkage disequilibrium between IL1B±511 and ILRN alleles. Interestingly, on a functional level, we obtained ®rst evidence that the IL-1B±511 polymorphism in¯uences the anti-in¯ammatory effects of IL-10. Thus, the ratio of secreted IL-1Ra to IL-1b in response to LPS and additional treatment with IL-10 was greater in PBMC cultures derived from homozygous carriers of IL1B±511*1 (CC genotype) than in those derived from carriers of at least one IL1B±511*2 allele (CT or TT genotype).
Taken together, these data indicate that promoter polymorphisms of the genes encoding TNF-a and IL-1b are associated with different psoriasis subgroups de®ned by early and late disease onset. They also support the concept that these subgroups rather than those de®ned by familial vs sporadic disease differ in their genetic background (Jenisch et al, 1998) . In addition, our study underlines the importance of controlling for parameters such as gender, age at onset, and family history, when investigating cytokine gene polymorphisms in psoriasis, and offers some explanation for the variation observed in previous studies with regard to the distribution of such polymorphisms among psoriatic patients (Arias et al, 1997; Hohler et al, 1997; Jacob et al, 1999; Reich et al, 1999) .
From the results of linkage analyses neither TNFA nor IL1B appear to represent major genes in psoriasis. The TNFA gene lies outside the 60 kb critical interval between HLA-C and the HCR gene on 6p21, which is suggested to contain the PSORS1 psoriasis susceptibility locus (OMIM: *177900) (Nair et al, 2000) . In light of the observed association of TNFA and IL1B promoter polymorphisms with early and late onset psoriasis subgroups, respectively, however, it is tempting to speculate that these polymorphisms may act as disease modi®ers involved in the determination of disease onset. Especially in the case of TNFA±238*2, the probable association with very early disease onset (< 25 y), the proin¯ammatory function in vitro, and the ®nding that this variant allele is part of the psoriasis-associated haplotype at 6p21 (Hohler et al, 1997; Jenisch et al, 1999) argue for a possible role in early disease manifestation. Accordingly, the previous observation of an association of HLA-Cw6 with early disease onset (Enerback et al, 1997) may re¯ect linkage disequilibrium between HLA-Cw6 and TNFA±238*2.
Clearly, there are several limitations to the ®ndings in this study. With regard to the functional role of TNFA and IL1B promoter polymorphisms, it has been shown that genetic relationships between polymorphic cytokine alleles and cytokine production may vary in patient groups compared with healthy controls (Koss et al, 2000) . In fact, Kaluza et al (2000) reported a decreased secretion of TNF-a in PBMC cultures derived from psoriatic patients carrying TNFA±238*2 in response to stimulation with anti-CD3 antibodies or streptococcal antigens. Therefore, further studies are necessary to explore fully the relationship between TNFA polymorphisms and TNF-a production in psoriasis. Also, it cannot be excluded that the dysregulation of IL-1b and TNF-a observed in psoriasis is related to other polymorphisms present in the IL1 and TNFA genes, and that IL1B±511*1 and TNFA±238*2 alleles are associated with psoriasis through linkage disequilibrium with such polymorphisms. For example, a rare TNFA promoter variant (A at ±376), that occurs in strict linkage with TNFA±238*2, was recently shown to introduce a binding site for the transcription factor OCT1 and to alter gene expression in human monocytes (Knight et al, 1999) . Finally, association results obtained from case±control studies might always be in¯uenced by population strati®cation. Deviation from Hardy±Weinberg equilibrium at the TNFA±308 locus with under-representation of TNFA±308*2 homozygotes has been observed in the control group collected by Hohler et al (1997) and interpreted as evidence that these controls are not a representative population sample (Jacob et al, 1999) . The ®nding of a similar deviation in our large independent control sample and the demonstration that carriage of TNFA±308*2 is associated with fatal outcome of common infectious diseases, including meningococcal disease in children (McGuire et al, 1994; Nadel et al, 1996) , however, point to negative selection as another possible explanation for this phenomenon. Large-scale family-based association studies are under way to support the association between psoriasis and polymorphisms in the TNFA and IL1B cytokine genes.
We thank Melanie Walter and Pia Ballhausen for excellent technical assistance. This work was supported by a grant from the Deutsche Forschungsgemeinschaft (Re 1475/1-1). Figure 3 . Frequency of TNFA±238 polymorphism depends on age of onset in male patients with psoriasis. Male patients with psoriasis were classi®ed in those with disease onset < 25 y, those with disease onset between 25 y and 49 y, and those with disease onset > 49 y of age. Bars represent the percentage of carriers of TNFA±238*2 in each of these groups compared with male controls. n, number of individuals investigated in each group.
